Atrial-selective drugs for treatment of atrial fibrillation

Haissaguerre M, Jais P, Shah DC et al (1998) Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 339:659–666 Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA (1995) Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 92:1954–1968 Dobrev D, Ravens U (2003) Remodeling of cardiomyocyte ion channels in human atrial fibrillation. Basic Res Cardiol 98:137–148 Savelieva I, Kourliouros A, Camm J (2010) Primary and secondary prevention of atrial fibrillation with statins and polyunsaturated fatty acids: review of evidence and clinical relevance. Naunyn Schmiedebergs Arch Pharmacol 381:207–219 Van Wagoner DR, Pond AL, Lamorgese M et al (1999) Atrial L-type Ca2+ currents and human atrial fibrillation. Circ Res 85:428–436 Dobrev D, Nattel S (2010) New antiarrhythmic drugs for treatment of atrial fibrillation. Lancet 375:1212–1223 Sun H, Leblanc N, Nattel S (1997) Mechanisms of inactivation of L-type calcium channels in human atrial myocytes. Am J Physiol 272:H1625–H1635 Brundel BJ, Gelder IC van, Henning RH et al (2001) Alterations in potassium channel gene expression in atria of patients with persistent and paroxysmal atrial fibrillation: differential regulation of protein and mRNA levels for K+ channels. J Am Coll Cardiol 37:926–932 Carnes CA, Janssen PM, Ruehr ML et al (2007) Atrial glutathione content, calcium current, and contractility. J Biol Chem 282:28063–28073 Christ T, Rauwolf T, Braun M et al (2004) Recording atrial monophasic action potentials using standard pacemaker leads: an alternative way to study electrophysiology properties of the human atrium in vivo? Pacing Clin Electrophysiol 27:1632–1637 Wyse DG, Waldo AL, DiMarco JP et al (2002) A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347:1825–1833 Vaughan Williams EM (1975) Classification of antidysrhythmic drugs. Pharmacol Ther B 1:115–138 Comtois P, Kneller J, Nattel S (2005) Of circles and spirals: bridging the gap between the leading circle and spiral wave concepts of cardiac reentry. Europace 7(Suppl 2):10–20 Allessie MA, Bonke FI, Schopman FJ (1977) Circus movement in rabbit atrial muscle as a mechanism of tachycardia. III. The “leading circle” concept: a new model of circus movement in cardiac tissue without the involvement of an anatomical obstacle. Circ Res 41:9–18 Echt DS, Liebson PR, Mitchell LB et al (1991) Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 324:781–788 Courtemanche M, Ramirez RJ, Nattel S (1998) Ionic mechanisms underlying human atrial action potential properties: insights from a mathematical model. Am J Physiol 275:H301–H321 Wettwer E, Hala O, Christ T et al (2004) Role of IKur in controlling action potential shape and contractility in the human atrium: influence of chronic atrial fibrillation. Circulation 110:2299–2306 Van Wagoner DR, Pond AL, McCarthy PM et al (1997) Outward K+ current densities and Kv1.5 expression are reduced in chronic human atrial fibrillation. Circ Res 80:772–781 Bosch RF, Zeng X, Grammer JB et al (1999) Ionic mechanisms of electrical remodeling in human atrial fibrillation. Cardiovasc Res 44:121–131 Christ T, Wettwer E, Voigt N et al (2008) Pathology-specific effects of the I(Kur)/I(to)/I(K,ACh) blocker AVE0118 on ion channels in human chronic atrial fibrillation. Br J Pharmacol 154:1619–1630 Ford JW, Milnes JT (2008) New drugs targeting the cardiac ultra-rapid delayed-rectifier current (I Kur): rationale, pharmacology and evidence for potential therapeutic value. J Cardiovasc Pharmacol 52:105–120 Dobrev D, Graf E, Wettwer E et al (2001) Molecular basis of downregulation of G-protein-coupled inward rectifying K+ current (IK,ACh) in chronic human atrial fibrillation: decrease in GIRK4 mRNA correlates with reduced I(K,ACh) and muscarinic receptor-mediated shortening of action potentials. Circulation 104:2551–2557 Allessie MA, Lammers WJ, Bonke IM, Hollen J (1984) Intra-atrial reentry as a mechanism for atrial flutter induced by acetylcholine and rapid pacing in the dog. Circulation 70:123–135 Ehrlich JR, Biliczki P, Hohnloser SH, Nattel S (2008) Atrial-selective approaches for the treatment of atrial fibrillation. J Am Coll Cardiol 51:787–792 Dobrev D, Friedrich A, Voigt N et al (2005) The G protein-gated potassium current I(K,ACh) is constitutively active in patients with chronic atrial fibrillation. Circulation 112:3697–3706 Burashnikov A, Di Diego JM, Zygmunt AC et al (2007) Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation 116:1449–1457 Siddiqui MA, Keam SJ (2006) Ranolazine: a review of its use in chronic stable angina pectoris. Drugs 66:693–710 Zaza A, Belardinelli L, Shryock JC (2008) Pathophysiology and pharmacology of the cardiac “late sodium current.” Pharmacol Ther 119:326–339 Sossalla S, Kallmeyer B, Wagner S et al (2010) Altered Na(+) currents in atrial fibrillation effects of ranolazine on arrhythmias and contractility in human atrial myocardium. J Am Coll Cardiol 55:2330–2342 Burashnikov A, Antzelevitch C (2009) Atrial-selective sodium channel block for the treatment of atrial fibrillation. Expert Opin Emerg Drugs 14:233–249 Marrouche NF, Reddy RK, Wittkowsky AK, Bardy GH (2000) High-dose bolus lidocaine for chemical cardioversion of atrial fibrillation: a prospective, randomized, double-blind crossover trial. Am Heart J 139:E8–E11 Voigt N, Rozmaritsa N, Trausch A et al (2010) Inhibition of I(K,ACh) current may contribute to clinical efficacy of class I and class III antiarrhythmic drugs in patients with atrial fibrillation. Naunyn Schmiedebergs Arch Pharmacol 381:251–259